[ CYTO ]
First question........ ALT-like projects have come and gone. If you think it's going to be great, fine. I don't. In fact, I feel that it's a money-consuming pit.
Second question........ OncoRad OV103, OncoScint OV103, OncoScint CR103, OncoTher, OncoRad PR358, OncoScint PR358, OncoScint BL372, OncoRad BL372, Thromboscan, OncoTc, OncoScint CR372, OncoScint PR356, OncoRad PR356, and many others.
A company doesn't go from $30/share in 92 to the the current 4 and change without a fair share of ugly efforts. You hold one of biotech's dilution holes. I wish CYTO luck in their effort at a turn things around, but, as I said, it's not difficult to find better business plans.
I was asked for my opinion. I gave it.
Rick |
